ReviewCell death & disease2026
Modulation of immune cells and metabolic reprogramming in efferocytosis.
Review in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efferocytosis: unifying pathogenic hub in metabolic disorders-mechanistic landscapes, targeted therapies and translational bottlenecks.Frontiers in immunology · 2026Review
- Efferocytosis in heart failure: Mechanisms, dysregulation and therapeutic potential.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Under physiological conditions, cell apoptosis is a silent death process during tissue renewal and remodeling. The phagocytosis of apoptotic cells, known as efferocytosis, is a key process performed primarily by macrophages and dendritic cells, as well as by non-professional phagocytes, such as epithelial cells and fibroblasts. This process, which involves the removal of apoptotic cells, is not just a routine task. It plays a significant role in producing anti-inflammatory mediators that are instrumental in maintaining tissue homeostasis. However, during infection, pathogens can induce different patterns of cell death, including apoptosis. Efferocytosis of infected apoptotic cells is a crucial part of the host defense mechanism. It aids in bacterial clearance, activates the effector functions of phagocytes, and directs the activation of CD4+T lymphocytes. The different stages of the efferocytosis process are not just a sequence of events, but a complex interplay that can interfere with the microenvironment by releasing soluble mediators ("find-me signals") as a rich source of nutrients for phagocytes during the digestion process ("digest-me"), such as amino acids, nucleotides, lipids, and carbohydrates. In recent years, several studies have contributed to unraveling the impact of the different stages of the efferocytosis process on regulating metabolic pathways that support the continuous phagocytosis of apoptotic cells, the activation profile, and the effector functions of phagocytes. In this review, we discuss the impact of efferocytosis on immune cells during homeostasis and infectious diseases, and in the metabolic reprogramming on phagocyte activation. We also explore the role of efferocytosis during the clearance of apoptotic cells in different pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.